Physician profile

Andrew H Chang

Diagnostic Radiology · Houston, TX

NPI 1326171489

$1,307.56

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$441.90
Food and Beverage$311.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $541.66 2023 Scopis Ent, Clarifix Cryotherapy Device
Guerbet LLC $216.48 2020
Abbott Laboratories $213.14 2021
Neurent Medical Limited $169.30 2024 Neuromark Device, Neuromark Radiofrequency Console
Bayer Healthcare Pharmaceuticals INC. $125.00 2022
Boston Scientific Corporation $25.33 2024
Sumitomo Pharma America, INC. $16.65 2023 Gemtesa

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Andrew H Chang

$1,307.56

in general payments reported 2019-2025

Years
2020-2024
Top company
Stryker Corporation

https://glasscript.com/doctor/458213/andrew-h-chang

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.